Effects of acetazolamide on congnitive performance during high-altitude exposure

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-12001890

Enrollment

Unknown

Registered

2012-01-18

Start date

2011-08-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

altitude neuropsychological impairment

Interventions

1:Placebo

2:Acetazolamide

Eligibility

Sex/Gender

All

Age

17 Years to 22 Years

Inclusion criteria

Inclusion criteria: 1. age 17–22 years; 2. living in Xi'an city with a home residence below 900 m; 3. no exposure to high-altitude (above 1500 m) since July, 2009; 4. no tobacco or recreational drug use; 5. total score of National College Entrance Examination (NCEE) above 500 (maximum score is 750) and mathematics score above 90 (maximum score is 150); 6. taking no medications such as methazolamide that might affect the study; 7. no chronic or genetic diseases; 8. willing to participate in the study and take the medicine provided; 9. no history of allergy to sulfonamides.

Exclusion criteria

Exclusion criteria: 1. obstructive lung disease; 2. heart disease; 3. liver or kidney dysfunction; 4. cerebrovascular disease; 5. obesity.

Design outcomes

Primary

Measure	Time frame
Neuropsychological test;	—

Countries

China

Contacts

Public ContactWenjing Luo

luowenj@fmmu.edu.cn+86 029 84774863

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026